Update to coagulopathy in COVID-19: Manifestations and management

Link to article at PubMed

Cleve Clin J Med. 2020 Dec 15. doi: 10.3949/ccjm.87a.ccc024-up. Online ahead of print.


Severe COVID-19 illness is associated with intense inflammation, leading to high rates of thrombotic complications that increase morbidity and mortality. Markedly elevated levels of D-dimer with normal fibrinogen levels are the hallmark laboratory findings of severe COVID-19-associated coagulopathy. Prophylaxis against venous thromboembolism is paramount for all hospitalized patients with COVID-19, with more aggressive prophylaxis and screening recommended for critically ill patients with D-dimer levels above 3.0 μg/mL. Point-of-care ultrasonography is the imaging method of choice for patients at high risk, as it entails minimal risk of exposing providers to the virus.

PMID:33323363 | DOI:10.3949/ccjm.87a.ccc024-up

Leave a Reply

Your email address will not be published. Required fields are marked *